» Articles » PMID: 31848331

Elimination of Fukutin Reveals Cellular and Molecular Pathomechanisms in Muscular Dystrophy-associated Heart Failure

Overview
Journal Nat Commun
Specialty Biology
Date 2019 Dec 19
PMID 31848331
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Heart failure is the major cause of death for muscular dystrophy patients, however, the molecular pathomechanism remains unknown. Here, we show the detailed molecular pathogenesis of muscular dystrophy-associated cardiomyopathy in mice lacking the fukutin gene (Fktn), the causative gene for Fukuyama muscular dystrophy. Although cardiac Fktn elimination markedly reduced α-dystroglycan glycosylation and dystrophin-glycoprotein complex proteins in sarcolemma at all developmental stages, cardiac dysfunction was observed only in later adulthood, suggesting that membrane fragility is not the sole etiology of cardiac dysfunction. During young adulthood, Fktn-deficient mice were vulnerable to pathological hypertrophic stress with downregulation of Akt and the MEF2-histone deacetylase axis. Acute Fktn elimination caused severe cardiac dysfunction and accelerated mortality with myocyte contractile dysfunction and disordered Golgi-microtubule networks, which were ameliorated with colchicine treatment. These data reveal fukutin is crucial for maintaining myocyte physiology to prevent heart failure, and thus, the results may lead to strategies for therapeutic intervention.

Citing Articles

Saturation mutagenesis-reinforced functional assays for disease-related genes.

Ma K, Huang S, Ng K, Lake N, Joseph S, Xu J Cell. 2024; 187(23):6707-6724.e22.

PMID: 39326416 PMC: 11568926. DOI: 10.1016/j.cell.2024.08.047.


Loss of connectin novex-3 leads to heart dysfunction associated with impaired cardiomyocyte proliferation and abnormal nuclear mechanics.

Hashimoto K, Ohira M, Kodama A, Kimoto M, Inoue M, Tone S Sci Rep. 2024; 14(1):13727.

PMID: 38877142 PMC: 11178842. DOI: 10.1038/s41598-024-64608-1.


Optimizing Embryo Collection for Application of CRISPR/Cas9 System and Generation of Fukutin Knockout Rat Using This Method.

Seol D, Park B, Koo D, Kim J, Jeon Y, Lee J Curr Issues Mol Biol. 2024; 46(5):3752-3762.

PMID: 38785502 PMC: 11120416. DOI: 10.3390/cimb46050234.


Matriglycan maintains t-tubule structural integrity in cardiac muscle.

Hord J, Anderson M, Prouty S, Melton S, Gastel Z, Zimmerman K Proc Natl Acad Sci U S A. 2024; 121(22):e2402890121.

PMID: 38771868 PMC: 11145246. DOI: 10.1073/pnas.2402890121.


Protein glycosylation in cardiovascular health and disease.

Chatham J, Patel R Nat Rev Cardiol. 2024; 21(8):525-544.

PMID: 38499867 DOI: 10.1038/s41569-024-00998-z.


References
1.
Murakami T, Hayashi Y, Noguchi S, Ogawa M, Nonaka I, Tanabe Y . Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Ann Neurol. 2006; 60(5):597-602. DOI: 10.1002/ana.20973. View

2.
Beedle A, Turner A, Saito Y, Lueck J, Foltz S, Fortunato M . Mouse fukutin deletion impairs dystroglycan processing and recapitulates muscular dystrophy. J Clin Invest. 2012; 122(9):3330-42. PMC: 3428090. DOI: 10.1172/JCI63004. View

3.
Michele D, Kabaeva Z, Davis S, Weiss R, Campbell K . Dystroglycan matrix receptor function in cardiac myocytes is important for limiting activity-induced myocardial damage. Circ Res. 2009; 105(10):984-93. PMC: 2783339. DOI: 10.1161/CIRCRESAHA.109.199489. View

4.
Bard F, Malhotra V . The formation of TGN-to-plasma-membrane transport carriers. Annu Rev Cell Dev Biol. 2006; 22:439-55. DOI: 10.1146/annurev.cellbio.21.012704.133126. View

5.
Frey N, Olson E . Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003; 65:45-79. DOI: 10.1146/annurev.physiol.65.092101.142243. View